Crizotinib was the first FDA-approved drug for ROS1-positive NSCLC, demonstrating significant clinical activity with high response rates and prolonged PFS, irrespective of the ROS1 fusion partner [137]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.